<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03873519</url>
  </required_header>
  <id_info>
    <org_study_id>R-2017/UEM11</org_study_id>
    <nct_id>NCT03873519</nct_id>
  </id_info>
  <brief_title>Acute Effect of Chromatic Environment During Chemotherapy</brief_title>
  <official_title>Acute Effect of Chromatic Environment During Chemotherapy Sessions on Health Status and Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad Europea de Madrid</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto Oncológico Balselga</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidad Europea de Madrid</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to examine the acute effect of color, room orientation (affecting
      amount of luminosity) on perceived health status and stress levels in oncologic patients
      during chemotherapy sessions at outpatient clinic. The secondary objectives will be to study
      the effect on vital signs (body temperature, heart rate, systolic blood pressure). Patients
      will be allocated into four conditions (Group A: Cold North, Group B: Cold South C: Warm
      North D: Warm South) for each session. For the next session, patients will be assigned a new
      condition. Assignment of sequences will be randomized for each patient.

      20 patients will be randomly assigned to one of the four groups, after having signed the Free
      and Informed Consent Form and agreed to participate in the project, will respond to the
      evaluation form and will be submitted to physical examination. Patients will be treated per
      standard of care.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2018</start_date>
  <completion_date type="Anticipated">December 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Patients will be allocated into four conditions (Group A: Cold North, Group B: Cold South C: Warm North D: Warm South), and they will be assigned a new condition at each next visit. The sequence will be assigned randomly to each patient. During each of the four visits, the patients will be treated per standard of care during their chemotherapy sessions. Outcome variables will be assessed before and after each visit.</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>EUROQOL-5D-5L questionnaire: Mobility</measure>
    <time_frame>5 minutes before to 5 minutes after chemotherapy session</time_frame>
    <description>The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement using a 1-digit number that expresses the level selected for that dimension.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EUROQOL-5D-5L questionnaire: Self-care</measure>
    <time_frame>5 minutes before to 5 minutes after chemotherapy session</time_frame>
    <description>The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement using a 1-digit number that expresses the level selected for that dimension.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EUROQOL-5D-5L questionnaire: Usual activities</measure>
    <time_frame>5 minutes before to 5 minutes after chemotherapy session</time_frame>
    <description>The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement using a 1-digit number that expresses the level selected for that dimension.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EUROQOL-5D-5L questionnaire: Pain/Discomfort</measure>
    <time_frame>5 minutes before to 5 minutes after chemotherapy session</time_frame>
    <description>The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement using a 1-digit number that expresses the level selected for that dimension.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EUROQOL-5D-5L questionnaire: Anxiety/Depression</measure>
    <time_frame>5 minutes before to 5 minutes after chemotherapy session</time_frame>
    <description>The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement using a 1-digit number that expresses the level selected for that dimension.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EUROQOL-5D-5L questionnaire: EQ-VAS</measure>
    <time_frame>5 minutes before to 5 minutes after chemotherapy session</time_frame>
    <description>The EQ VAS is an independent subscale of the EUROQOL-5D-5L questionnaire, which uses a vertical visual analogue scale format. The EQ VAS is used for recording the self-rated health on a range from 0 to 100, where the endpoints are labelled 'The best health you can imagine' (100) and 'The worst health you can imagine' (0). The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ID-Pain questionnaire</measure>
    <time_frame>5 minutes before to 5 minutes after chemotherapy session</time_frame>
    <description>Assessment of neuropathic pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs: body temperature</measure>
    <time_frame>5 minutes before to 5 minutes after chemotherapy session</time_frame>
    <description>Per standard of care, in Celsius</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs: blood pressure</measure>
    <time_frame>5 minutes before to 5 minutes after chemotherapy session</time_frame>
    <description>Per standard of care, in mm Hg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs: heart rate</measure>
    <time_frame>5 minutes before to 5 minutes after chemotherapy session</time_frame>
    <description>Per standard of care, in beats per minute</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Cold North</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group A: Cold color scheme, room facing North</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cold South</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group B:Cold color scheme, room facing South</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Warm North</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group C: Warm color scheme, room facing North</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Warm South</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group D: Warm color scheme, room facing South</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Chromatic Environment</intervention_name>
    <description>Rooms where chemotherapy sessions are delivered will be modified to show warm/cold color temperature in walls and equipment.</description>
    <arm_group_label>Cold North</arm_group_label>
    <arm_group_label>Cold South</arm_group_label>
    <arm_group_label>Warm North</arm_group_label>
    <arm_group_label>Warm South</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Room Orientation</intervention_name>
    <description>Room will be facing North or South</description>
    <arm_group_label>Cold North</arm_group_label>
    <arm_group_label>Cold South</arm_group_label>
    <arm_group_label>Warm North</arm_group_label>
    <arm_group_label>Warm South</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Age 18-89 years

          -  Diagnosed with breast cancer that required chemotherapy

          -  Followed in outpatient clinic

        Exclusion criteria:

          -  Diagnosed color blindness

          -  Undergoing treatment with antidepressants
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margarita Pérez Ruiz, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Universidad Europea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paula Gomez Vela, BS</last_name>
    <phone>+34620820447</phone>
    <email>paulagvela@velasalvadorarquitectos.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Margarita Pérez Ruiz, MD,PhD</last_name>
    <phone>+34649084705</phone>
    <email>margarita.perez@universidadeuropea.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Ruber Internacional</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Almudena Corredera, RN</last_name>
      <phone>912986250</phone>
      <email>almudena.corredera@iob-onco.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 11, 2018</study_first_submitted>
  <study_first_submitted_qc>March 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2019</study_first_posted>
  <last_update_submitted>March 30, 2020</last_update_submitted>
  <last_update_submitted_qc>March 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad Europea de Madrid</investigator_affiliation>
    <investigator_full_name>Margarita Perez</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>chemotherapy</keyword>
  <keyword>vital signs</keyword>
  <keyword>stress</keyword>
  <keyword>health status</keyword>
  <keyword>healing environment</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

